Histopathological determinants of tumor resistance: A special look to the immunohistochemical expression of carbonic anhydrase ix in human cancers

Current Medicinal Chemistry

Volumn 21, Issue 14, 2014, Pages 1569-1582

  Ilardi, G ^a   Zambrano, N ^b   Merolla, F ^a   Siano, M ^a   Varricchio, S ^a   Vecchione, M ^a   De Rosa, G ^a   Mascolo, M ^a   Staibano, S ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

CA IX Carbonic anhydrase; Clinical pathological features and biological outcome; Hypoxia; Immunohistochemistry; Solid human cancers; Stem cells markers; Targeted therapy

Indexed keywords

CARBONATE DEHYDRATASE IX; HERMES ANTIGEN; NESTIN; CARBONATE DEHYDRATASE;

ACIDOSIS; ADVANCED CANCER; CANCER RESISTANCE; CANCER STEM CELL; CELL HYPOXIA; CELL PH; CELL POPULATION; CYTOPLASM; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MESENCHYME; METASTASIS; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TUMOR INVASION; TUMOR MICROENVIRONMENT; DRUG RESISTANCE; ENZYMOLOGY; METABOLISM; NEOPLASM; PATHOLOGY;

CARBONIC ANHYDRASES; CELL HYPOXIA; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84899859103     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990227     Document Type: Review

References (168)

1. Garraway, L.A.; Verwey, J.; Ballman, K. Precision Oncology: An Overview. J. Clin. Oncol., 2013, 31(15), 1803-1805.
2. Bray, F.; Jemal, A.; Grey, N.; Ferlay, J.; Forman, D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol., 2012, 13(8), 790-801.
3. Fox, E.J.; Salk, J.J.; Loeb, L.A. Cancer genome sequencing-an interim analysis. Cancer Res., 2009, 69(12), 4948-4950.
4. Gerlinger, M.; Swanton, C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Brit. J. Cancer, 2010, 103(8), 1139-1143.
5. Klein, C.A. Random mutations, selected mutations: A PIN opens the door to new genetic landscapes. Proc. Natl. Acad. Sci. USA., 2006, 103(48), 18033-18034.
6. Chaffer, C.L.; Brueckmann, I.; Scheel, C.; Kaestli, A.J.; Wiggins, P.A.; Rodrigues, L.O.; Brooks, M.; Reinhardt, F.; Su, Y.; Polyak, K.; Arendt, L.M.; Kuperwasser, C.; Bierie, B.; Weinberg, R.A. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. USA., 2011, 108(19), 7950-7955.
7. Gupta, P.B.; Fillmore, C.M.; Jiang, G.; Shapira, S.D.; Tao, K.; Kuperwasser, C.; Lander, E.S. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell, 2011, 146(4), 633-644.
8. Roesch, A.; Fukunaga-Kalabis, M.; Schmidt, E.C.; Zabierowski, S.E.; Brafford, P.A.; Vultur, A.; Basu, D.; Gimotty, P.; Vogt, T.; Herlyn, M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell, 2010, 141(4), 583-594.
9. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2(1), 48-58.
10. Fukuda, Y.; Schuetz, J.D. ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem. Pharmacol., 2012, 83(8), 1073-1083.
11. Rocco, A.; Compare, D.; Liguori, E.; Cianflone, A.; Pirozzi, G.; Tirino, V.; Bertoni, A.; Santoriello, M.; Garbi, C.; D'Armiento, M.; Staibano, S.; Nardone, G. MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells. Lab. Invest., 2012, 92(10), 1407-1418.
12. Ni Chonghaile, T.; Letai, A. Mimicking the BH3 domain to kill cancer cells. Oncogene, 2008, 27 Suppl 1, S149-S157.
13. Engelman, J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer, 2009, 9(8), 550-562.
14. Saunders, N.A.; Simpson, F.; Thompson, E.W.; Hill, M.M.; Endo-Munoz, L.; Leggatt, G.; Minchin, R.F.; Guminski, A. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol. Med., 2012, 4(8), 675-684.
15. Teicher, B.A. Acute and chronic in vivo therapeutic resistance. Biochem. Pharmacol., 2009, 77(11), 1665-1673.
16. Jubb, A.M.; Buffa, F.M.; Harris, A.L. Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J. Cell. Mol. Med., 2010, 14(1-2), 18-29.
17. Potenta, S.; Zeisberg, E.; Kalluri, R. The role of endothelial- tomesenchymal transition in cancer progression. Brit. J. Cancer, 2008, 99(9), 1375-1379.
18. Azad, M.B.; Chen, Y.; Henson, E.S.; Cizeau, J.; McMillan-Ward, E.; Israels, S.J.; Gibson, S.B. Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy, 2008, 4(2), 195-204.
19. Hu, Y.L.; Jahangiri, A.; De Lay, M.; Aghi, M.K. Hypoxia-induced tumor cell autophagy mediates resistance to anti-angiogenic therapy. Autophagy, 2012, 8(6), 979-981.
20. Kim, J.W.; Gao, P.; Dang, C.V. Effects of hypoxia on tumor metabolism. Cancer Metast. Rev., 2007, 26(2), 291-298.
21. Chen, Z.; Lu, W.; Garcia-Prieto, C.; Huang, P. The Warburg effect and its cancer therapeutic implications. J. Bioenerget. Biomembr., 2007, 39(3), 267-274.
22. Vaupel, P.; Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metast. Rev., 2007, 26(2), 225-239.
23. Bache, M.; Kappler, M.; Said, H.M.; Staab, A.; Vordermark, D. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr. Med. Chem., 2008, 15(4), 322-338.
24. Lendahl, U.; Lee, K.L.; Yang, H.; Poellinger, L. Generating specificity and diversity in the transcriptional response to hypoxia. Nat. Rev. Genet., 2009, 10(12), 821-832.
25. Pastorek, J.; Pastorekova, S.; Callebaut, I.; Mornon, J.P.; Zelnik, V.; Opavsky, R.; Zat'ovicova, M.; Liao, S.; Portetelle, D.; Stanbridge, E.J.; et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene, 1994, 9(10), 2877-2888.
26. De Simone, G.; Supuran, C.T. Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target. Biochim. Biophys. Acta, 2010, 1804(2), 404-409.
27. Supuran, C.T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov., 2008, 7(2), 168-181.
28. Swietach, P.; Patiar, S.; Supuran, C.T.; Harris, A.L.; Vaughan-Jones, R.D. The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J. Biol. Chem., 2009, 284(30), 20299-20310.
29. Neri, D.; Supuran, C.T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov., 2011, 10(10), 767-777.
30. Fang, J.S.; Gillies, R.D.; Gatenby, R.A. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin. Cancer Biol., 2008, 18(5), 330-337.
31. Gatenby, R.A.; Gillies, R.J. A microenvironmental model of carcinogenesis. Nat. Rev. Cancer, 2008, 8(1), 56-61.
32. Gillies, R.J.; Gatenby, R.A. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metast. Rev., 2007, 26(2), 311-317.
33. Ivanov, S.V.; Kuzmin, I.; Wei, M.H.; Pack, S.; Geil, L.; Johnson, B.E.; Stanbridge, E.J.; Lerman, M.I. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. USA., 1998, 95(21), 12596-12601.
34. Parks, S.K.; Chiche, J.; Pouyssegur, J. pH control mechanisms of tumor survival and growth. J. Cell. Physiol., 2011, 226(2), 299-308.
35. Swietach, P.; Hulikova, A.; Vaughan-Jones, R.D.; Harris, A.L. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene, 2010, 29(50), 6509-6521.
36. Stubbs, M.; McSheehy, P.M.; Griffiths, J.R.; Bashford, C.L. Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today, 2000, 6(1), 15-19.
37. Fukumura, D.; Xu, L.; Chen, Y.; Gohongi, T.; Seed, B.; Jain, R.K. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res., 2001, 61(16), 6020-6024.
38. Kato, Y.; Nakayama, Y.; Umeda, M.; Miyazaki, K. Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J. Biol. Chem., 1992, 267(16), 11424-11430.
39. Martinez-Zaguilan, R.; Seftor, E.A.; Seftor, R.E.; Chu, Y.W.; Gillies, R.J.; Hendrix, M.J. Acidic pH enhances the invasive behavior of human melanoma cells. Clin. Exp. Metast., 1996, 14(2), 176-186.
40. Fischer, B.; Muller, B.; Fischer, K.G.; Baur, N.; Kreutz, W. Acidic pH inhibits non-MHC-restricted killer cell functions. Clin. Immunol., 2000, 96(3), 252-263.
41. Chiche, J.; Ilc, K.; Laferriere, J.; Trottier, E.; Dayan, F.; Mazure, N.M.; Brahimi-Horn, M.C.; Pouyssegur, J. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res., 2009, 69(1), 358-368.
42. Mueller, M.M.; Fusenig, N.E. Friends or foes -bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer, 2004, 4(11), 839-849.
43. Svastova, E.; Zilka, N.; Zat'ovicova, M.; Gibadulinova, A.; Ciampor, F.; Pastorek, J.; Pastorekova, S. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp. Cell Res., 2003, 290(2), 332-345.
44. Shin, H.J.; Rho, S.B.; Jung, D.C.; Han, I.O.; Oh, E.S.; Kim, J.Y. Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion. J. Cell Sci., 2011, 124(Pt 7), 1077-1087.
45. Liao, S.Y.; Lerman, M.I.; Stanbridge, E.J. Expression of transmembrane carbonic anhydrases, CAIX and CAXII, in human development. BMC Develop. Biol., 2009, 9, 22.
46. Hilvo, M.; Rafajova, M.; Pastorekova, S.; Pastorek, J.; Parkkila, S. Expression of carbonic anhydrase IX in mouse tissues. J. Histochem. Cytochem., 2004, 52(10), 1313-1322.
47. Saarnio, J.; Parkkila, S.; Parkkila, A.K.; Waheed, A.; Casey, M.C.; Zhou, X.Y.; Pastorekova, S.; Pastorek, J.; Karttunen, T.; Haukipuro, K.; Kairaluoma, M.I.; Sly, W.S. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J. Histochem. Cytochem., 1998, 46(4), 497-504.
48. Kaluz, S.; Kaluzova, M.; Liao, S.Y.; Lerman, M.; Stanbridge, E.J. Transcriptional control of the tumor-and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim. Biophys. Acta, 2009, 1795(2), 162-172.
49. Karhumaa, P.; Kaunisto, K.; Parkkila, S.; Waheed, A.; Pastorekova, S.; Pastorek, J.; Sly, W.S.; Rajaniemi, H. Expression of the transmembrane carbonic anhydrases, CA IX and CA XII, in the human male excurrent ducts. Mol. Human Reprod., 2001, 7(7), 611-616.
50. Kivela, A.J.; Parkkila, S.; Saarnio, J.; Karttunen, T.J.; Kivela, J.; Parkkila, A.K.; Pastorekova, S.; Pastorek, J.; Waheed, A.; Sly, W.S.; Rajaniemi, H. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem. Cell Biol., 2000, 114(3), 197-204.
51. Mastrolorenzo, A.; Zuccati, G.; Massi, D.; Gabrielli, M.G.; Casini, A.; Scozzafava, A.; Supuran, C.T. Immunohistochemical study of carbonic anhydrase isozymes in human skin. Eur. J. Dermatol., 2003, 13(5), 440-444.
52. Swinson, D.E.; Jones, J.L.; Richardson, D.; Wykoff, C.; Turley, H.; Pastorek, J.; Taub, N.; Harris, A.L.; O'Byrne, K.J. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J. Clin. Oncol., 2003, 21(3), 473-482.
53. Kim, S.J.; Rabbani, Z.N.; Dewhirst, M.W.; Vujaskovic, Z.; Vollmer, R.T.; Schreiber, E.G.; Oosterwijk, E.; Kelley, M.J. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer, 2005, 49(3), 325-335.
54. Ilie, M.; Mazure, N.M.; Hofman, V.; Ammadi, R.E.; Ortholan, C.; Bonnetaud, C.; Havet, K.; Venissac, N.; Mograbi, B.; Mouroux, J.; Pouyssegur, J.; Hofman, P. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Brit. J. Cancer, 2010, 102(11), 1627-1635.
55. Saarnio, J.; Parkkila, S.; Parkkila, A.K.; Haukipuro, K.; Pastorekova, S.; Pastorek, J.; Kairaluoma, M.I.; Karttunen, T.J. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am. J. Pathol., 1998, 153(1), 279-285.
56. Korkeila, E.; Talvinen, K.; Jaakkola, P.M.; Minn, H.; Syrjanen, K.; Sundstrom, J.; Pyrhonen, S. Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Brit. J. Cancer, 2009, 100(6), 874-880.
57. Chia, S.K.; Wykoff, C.C.; Watson, P.H.; Han, C.; Leek, R.D.; Pastorek, J.; Gatter, K.C.; Ratcliffe, P.; Harris, A.L. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol., 2001, 19(16), 3660-3668.
58. Trastour, C.; Benizri, E.; Ettore, F.; Ramaioli, A.; Chamorey, E.; Pouyssegur, J.; Berra, E. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int. J. Cancer, 2007, 120(7), 1451-1458.
59. Tan, E.Y.; Yan, M.; Campo, L.; Han, C.; Takano, E.; Turley, H.; Candiloro, I.; Pezzella, F.; Gatter, K.C.; Millar, E.K.; O'Toole, S.A.; McNeil, C.M.; Crea, P.; Segara, D.; Sutherland, R.L.; Harris, A.L.; Fox, S.B. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Brit. J. Cancer, 2009, 100(2), 405-411.
60. Loncaster, J.A.; Harris, A.L.; Davidson, S.E.; Logue, J.P.; Hunter, R.D.; Wycoff, C.C.; Pastorek, J.; Ratcliffe, P.J.; Stratford, I.J.; West, C.M. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res., 2001, 61(17), 6394-6399.
61. Kim, J.Y.; Shin, H.J.; Kim, T.H.; Cho, K.H.; Shin, K.H.; Kim, B.K.; Roh, J.W.; Lee, S.; Park, S.Y.; Hwang, Y.J.; Han, I.O. Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. J. Cancer Res. Clin. Oncol., 2006, 132(5), 302-308.
62. Lee, S.; Shin, H.J.; Han, I.O.; Hong, E.K.; Park, S.Y.; Roh, J.W.; Shin, K.H.; Kim, T.H.; Kim, J.Y. Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer. Cancer Sci., 2007, 98(3), 329-333.
63. Woelber, L.; Kress, K.; Kersten, J.F.; Choschzick, M.; Kilic, E.; Herwig, U.; Lindner, C.; Schwarz, J.; Jaenicke, F.; Mahner, S.; Milde-Langosch, K.; Mueller, V.; Ihnen, M. Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer. BMC Cancer, 2011, 11, 12.
64. Hoskin, P.J.; Sibtain, A.; Daley, F.M.; Wilson, G.D. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Brit. J. Cancer, 2003, 89(7), 1290-1297.
65. Choschzick, M.; Oosterwijk, E.; Muller, V.; Woelber, L.; Simon, R.; Moch, H.; Tennstedt, P. Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Archiv., 2011, 459(2), 193-200.
66. Nordfors, K.; Haapasalo, J.; Korja, M.; Niemela, A.; Laine, J.; Parkkila, A.K.; Pastorekova, S.; Pastorek, J.; Waheed, A.; Sly, W.S.; Parkkila, S.; Haapasalo, H. The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis. BMC Cancer, 2010, 10, 148.
67. Hoogsteen, I.J.; Marres, H.A.; Wijffels, K.I.; Rijken, P.F.; Peters, J.P.; van den Hoogen, F.J.; Oosterwijk, E.; van der Kogel, A.J.; Kaanders, J.H. Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin. Cancer Res., 2005, 11(1), 97-106.
68. De Schutter, H.; Landuyt, W.; Verbeken, E.; Goethals, L.; Hermans, R.; Nuyts, S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/-chemotherapy. BMC Cancer, 2005, 5, 42.
69. Koukourakis, M.I.; Bentzen, S.M.; Giatromanolaki, A.; Wilson, G.D.; Daley, F.M.; Saunders, M.I.; Dische, S.; Sivridis, E.; Harris, A.L. Endogenous markers of two separate hypoxia response path ways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J. Clin. Oncol., 2006, 24(5), 727-735.
70. Eckert, A.W.; Lautner, M.H.; Schutze, A.; Bolte, K.; Bache, M.; Kappler, M.; Schubert, J.; Taubert, H.; Bilkenroth, U. Coexpression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. J. Oral Pathol. Med., 2010, 39(4), 313-317.
71. Choi, S.W.; Kim, J.Y.; Park, J.Y.; Cha, I.H.; Kim, J.; Lee, S. Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. Human Pathol., 2008, 39(9), 1317-1322.
72. Hussain, S.A.; Ganesan, R.; Reynolds, G.; Gross, L.; Stevens, A.; Pastorek, J.; Murray, P.G.; Perunovic, B.; Anwar, M.S.; Billingham, L.; James, N.D.; Spooner, D.; Poole, C.J.; Rea, D.W.; Palmer, D.H. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Brit. J. Cancer, 2007, 96(1), 104-109.
73. Klatte, T.; Seligson, D.B.; Rao, J.Y.; Yu, H.; de Martino, M.; Kawaoka, K.; Wong, S.G.; Belldegrun, A.S.; Pantuck, A.J. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer, 2009, 115(7), 1448-1458.
74. Haapasalo, J.A.; Nordfors, K.M.; Hilvo, M.; Rantala, I.J.; Soini, Y.; Parkkila, A.K.; Pastorekova, S.; Pastorek, J.; Parkkila, S.M.; Haapasalo, H.K. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin. Cancer Res., 2006, 12(2), 473-477.
75. Koukourakis, M.I.; Giatromanolaki, A.; Sivridis, E.; Simopoulos, K.; Pastorek, J.; Wykoff, C.C.; Gatter, K.C.; Harris, A.L. Hypoxiaregulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin. Cancer Res., 2001, 7(11), 3399-3403.
76. Hedley, D.; Pintilie, M.; Woo, J.; Morrison, A.; Birle, D.; Fyles, A.; Milosevic, M.; Hill, R. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin. Cancer Res., 2003, 9(15), 5666-5674.
77. Bui, M.H.; Seligson, D.; Han, K.R.; Pantuck, A.J.; Dorey, F.J.; Huang, Y.; Horvath, S.; Leibovich, B.C.; Chopra, S.; Liao, S.Y.; Stanbridge, E.; Lerman, M.I.; Palotie, A.; Figlin, R.A.; Belldegrun, A.S. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res., 2003, 9(2), 802-811.
78. Giatromanolaki, A.; Koukourakis, M.I.; Sivridis, E.; Pastorek, J.; Wykoff, C.C.; Gatter, K.C.; Harris, A.L. Expression of hypoxiainducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res., 2001, 61(21), 7992-7998.
79. Supuran, C.T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev., 2003, 23(2), 146-189.
80. Brennan, D.J.; Jirstrom, K.; Kronblad, A.; Millikan, R.C.; Landberg, G.; Duffy, M.J.; Ryden, L.; Gallagher, W.M.; O'Brien, S.L. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin. Cancer Res., 2006, 12(21), 6421-6431.
81. Proescholdt, M.A.; Merrill, M.J.; Stoerr, E.M.; Lohmeier, A.; Pohl, F.; Brawanski, A. Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro-Oncol., 2012, 14(11), 1357-1366.
82. Ahlskog, J.K.; Schliemann, C.; Marlind, J.; Qureshi, U.; Ammar, A.; Pedley, R.B.; Neri, D. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Brit. J. Cancer, 2009, 101(4), 645-657.
83. Dubois, L.; Lieuwes, N.G.; Maresca, A.; Thiry, A.; Supuran, C.T.; Scozzafava, A.; Wouters, B.G.; Lambin, P. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother. Oncol., 2009, 92(3), 423-428.
84. Parkkila, S.; Innocenti, A.; Kallio, H.; Hilvo, M.; Scozzafava, A.; Supuran, C.T. The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. Bioorg. Med. Chem. Lett., 2009, 19(15), 4102-4106.
85. Nieto, M.A. The ins and outs of the epithelial to mesenchymal transition in health and disease. Ann. Rev. Cell Develop. Biol., 2011, 27, 347-376.
86. Thomson, S.; Buck, E.; Petti, F.; Griffin, G.; Brown, E.; Ramnarine, N.; Iwata, K.K.; Gibson, N.; Haley, J.D. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res., 2005, 65(20), 9455-9462.
87. Thomson, S.; Petti, F.; Sujka-Kwok, I.; Epstein, D.; Haley, J.D. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin. Exp. Metast., 2008, 25(8), 843-854.
88. Yauch, R.L.; Januario, T.; Eberhard, D.A.; Cavet, G.; Zhu, W.; Fu, L.; Pham, T.Q.; Soriano, R.; Stinson, J.; Seshagiri, S.; Modrusan, Z.; Lin, C.Y.; O'Neill, V.; Amler, L.C. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res., 2005, 11(24 Pt 1), 8686-8698.
89. Yao, Z.; Fenoglio, S.; Gao, D.C.; Camiolo, M.; Stiles, B.; Lindsted, T.; Schlederer, M.; Johns, C.; Altorki, N.; Mittal, V.; Kenner, L.; Sordella, R. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl. Acad. Sci. USA., 2010, 107(35), 15535-15540.
90. Cheng, G.Z.; Chan, J.; Wang, Q.; Zhang, W.; Sun, C.D.; Wang, L.H. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res., 2007, 67(5), 1979-1987.
91. Hsu, D.S.; Lan, H.Y.; Huang, C.H.; Tai, S.K.; Chang, S.Y.; Tsai, T.L.; Chang, C.C.; Tzeng, C.H.; Wu, K.J.; Kao, J.Y.; Yang, M.H. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin. Cancer Res., 2010, 16(18), 4561-4571.
92. Latifi, A.; Abubaker, K.; Castrechini, N.; Ward, A.C.; Liongue, C.; Dobill, F.; Kumar, J.; Thompson, E.W.; Quinn, M.A.; Findlay, J.K.; Ahmed, N. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J. Cell. Biochem., 2011, 112(10), 2850-2864.
93. Arumugam, T.; Ramachandran, V.; Fournier, K.F.; Wang, H.; Marquis, L.; Abbruzzese, J.L.; Gallick, G.E.; Logsdon, C.D.; McConkey, D.J.; Choi, W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res., 2009, 69(14), 5820-5828.
94. Das, B.; Tsuchida, R.; Malkin, D.; Koren, G.; Baruchel, S.; Yeger, H. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells, 2008, 26(7), 1818-1830.
95. Brahimi-Horn, M.C.; Bellot, G.; Pouyssegur, J. Hypoxia and energetic tumour metabolism. Curr. Opin. Genet. Develop., 2011, 21(1), 67-72.
96. Chamorro, M.N.; Schwartz, D.R.; Vonica, A.; Brivanlou, A.H.; Cho, K.R.; Varmus, H.E. FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J., 2005, 24(1), 73-84.
97. Kuang, H.B.; Miao, C.L.; Guo, W.X.; Peng, S.; Cao, Y.J.; Duan, E.K. Dickkopf-1 enhances migration of HEK293 cell by betacatenin/E-cadherin degradation. Front. Biosci., 2009, 14, 2212-2220.
98. Schlessinger, K.; Hall, A.; Tolwinski, N. Wnt signaling pathways meet Rho GTPases. Gene. Develop., 2009, 23(3), 265-277.
99. Orsulic, S.; Huber, O.; Aberle, H.; Arnold, S.; Kemler, R. Ecadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1- mediated transactivation. J. Cell Sci., 1999, 112( Pt 8), 1237-1245.
100. Lock, F.E.; McDonald, P.C.; Lou, Y.; Serrano, I.; Chafe, S.C.; Ostlund, C.; Aparicio, S.; Winum, J.Y.; Supuran, C.T.; Dedhar, S. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene, 2013, 32(44), 5210-5219.
101. Moore, S.R.; Johnson, N.W.; Pierce, A.M.; Wilson, D.F. The epidemiology of tongue cancer: a review of global incidence. Oral Dis., 2000, 6(2), 75-84.
102. Blanpain, C.; Horsley, V.; Fuchs, E. Epithelial stem cells: turning over new leaves. Cell, 2007, 128(3), 445-458.
103. Martens, J.E.; Smedts, F.; van Muyden, R.C.; Schoots, C.; Helmerhorst, T.J.; Hopman, A.; Ramaekers, F.C.; Arends, J.W. Reserve cells in human uterine cervical epithelium are derived from mullerian epithelium at midgestational age. Int. J. Gynecol. Pathol., 2007, 26(4), 463-468.
104. Staibano, S.; Mignogna, C.; Lo Muzio, L.; Mascolo, M.; Salvatore, G.; Di Benedetto, M.; Califano, L.; Rubini, C.; De Rosa, G. Chromatin assembly factor-1 (CAF-1)-mediated regulation of cell proliferation and DNA repair: a link with the biological behaviour of squamous cell carcinoma of the tongue? Histopathology, 2007, 50(7), 911-919.
105. Staibano, S.; Mascolo, M.; Di Benedetto, M.; Vecchione, M.L.; Ilardi, G.; Di Lorenzo, G.; Autorino, R.; Salerno, V.; Morena, A.; Rocco, A.; Turco, M.C.; Morelli, E. BAG3 protein delocalisation in prostate carcinoma. Tumour Biol., 2010, 31(5), 461-469.
106. Donato, D.P.; Johnson, M.T.; Yang, X.J.; Zynger, D.L. Expression of carbonic anhydrase IX in genitourinary and adrenal tumours. Histopathology, 2011, 59(6), 1229-1239.
107. Smyth, L.G.; O'Hurley, G.; O'Grady, A.; Fitzpatrick, J.M.; Kay, E.; Watson, R.W. Carbonic anhydrase IX expression in prostate cancer. Prostate Cancer Prostatic Dis., 2010, 13(2), 178-181.
108. Chopra, S.; Foltz, W.D.; Milosevic, M.F.; Toi, A.; Bristow, R.G.; Menard, C.; Haider, M.A. Comparing oxygen-sensitive MRI (BOLD R2) with oxygen electrode measurements: a pilot study in men with prostate cancer. Int. J. Rad. Biol., 2009, 85(9), 805-813.
109. Cleven, A.H.; van Engeland, M.; Wouters, B.G.; de Bruine, A.P. Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas. Cell. Oncol., 2007, 29(3), 229-240.
110. Cleven, A.H.; Wouters, B.G.; Schutte, B.; Spiertz, A.J.; van Engeland, M.; de Bruine, A.P. Poorer outcome in stromal HIF-2 alpha-and CA9-positive colorectal adenocarcinomas is associated with wild-type TP53 but not with BNIP3 promoter hypermethylation or apoptosis. Brit. J. Cancer, 2008, 99(5), 727-733.
111. Colpaert, C.G.; Vermeulen, P.B.; Fox, S.B.; Harris, A.L.; Dirix, L.Y.; Van Marck, E.A. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res. Treat., 2003, 81(2), 137-147.
112. Tomes, L.; Emberley, E.; Niu, Y.; Troup, S.; Pastorek, J.; Strange, K.; Harris, A.; Watson, P.H. Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res. Treat., 2003, 81(1), 61-69.
113. Brockton, N.; Dort, J.; Lau, H.; Hao, D.; Brar, S.; Klimowicz, A.; Petrillo, S.; Diaz, R.; Doll, C.; Magliocco, A. High stromal carbonic anhydrase IX expression is associated with decreased survival in P16-negative head-and-neck tumors. Int. J. Rad. Oncol. Biol. Phys., 2011, 80(1), 249-257.
114. Perez-Sayans, M.; Suarez-Penaranda, J.M.; Pilar, G.D.; Supuran, C.T.; Pastorekova, S.; Barros-Angueira, F.; Gandara-Rey, J.M.; Garcia-Garcia, A. Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients. J. Oral Pathol. Med., 2012, 41(9), 667-674.
115. Zheng, G.; Zhou, M.; Ou, X.; Peng, B.; Yu, Y.; Kong, F.; Ouyang, Y.; He, Z. Identification of carbonic anhydrase 9 as a contributor to pingyangmycin-induced drug resistance in human tongue cancer cells. FEBS J., 2010, 277(21), 4506-4518.
116. Kim, S.J.; Shin, H.J.; Jung, K.Y.; Baek, S.K.; Shin, B.K.; Choi, J.; Kim, B.S.; Shin, S.W.; Kim, Y.H.; Kim, J.S.; Oosterwijk, E. Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn. J. Clin. Oncol., 2007, 37(11), 812-819.
117. Le, Q.T.; Kong, C.; Lavori, P.W.; O'Byrne, K.; Erler, J.T.; Huang, X.; Chen, Y.; Cao, H.; Tibshirani, R.; Denko, N.; Giaccia, A.J.; Koong, A.C. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int. J. Rad. Oncol. Biol. Phys., 2007, 69(1), 167-175.
118. Peridis, S.; Pilgrim, G.; Athanasopoulos, I.; Parpounas, K. Carbonic anhydrase-9 expression in head and neck cancer: a metaanalysis. Eur. Arch. Otorhinolaryngol., 2011, 268(5), 661-670.
119. Kong, C.S.; Narasimhan, B.; Cao, H.; Kwok, S.; Erickson, J.P.; Koong, A.; Pourmand, N.; Le, Q.T. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int. J. Rad. Oncol. Biol. Phys., 2009, 74(2), 553-561.
120. Eriksen, J.G.; Overgaard, J. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother. Oncol., 2007, 83(3), 383-388.
121. Day, G.L.; Blot, W.J. Second primary tumors in patients with oral cancer. Cancer, 1992, 70(1), 14-19.
122. Parkin, D.M.; Laara, E.; Muir, C.S. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int. J. Cancer, 1988, 41(2), 184-197.
123. Carvalho, A.L.; Nishimoto, I.N.; Califano, J.A.; Kowalski, L.P. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int. J. Cancer, 2005, 114(5), 806-816.
124. Ivanov, S.; Liao, S.Y.; Ivanova, A.; Danilkovitch-Miagkova, A.; Tarasova, N.; Weirich, G.; Merrill, M.J.; Proescholdt, M.A.; Oldfield, E.H.; Lee, J.; Zavada, J.; Waheed, A.; Sly, W.; Lerman, M.I.; Stanbridge, E.J. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol., 2001, 158(3), 905-919.
125. Robertson, N.; Potter, C.; Harris, A.L. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res., 2004, 64(17), 6160-6165.
126. Shi, Q.; Le, X.; Wang, B.; Abbruzzese, J.L.; Xiong, Q.; He, Y.; Xie, K. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene, 2001, 20(28), 3751-3756.
127. Roshy, S.; Sloane, B.F.; Moin, K. Pericellular cathepsin B and malignant progression. Cancer Metast. Rev., 2003, 22(2-3), 271-286.
128. Rozhin, J.; Sameni, M.; Ziegler, G.; Sloane, B.F. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res., 1994, 54(24), 6517-6525.
129. Gieling, R.G.; Williams, K.J. Carbonic anhydrase IX as a target for metastatic disease. Bioorg. Med. Chem., 2013, 21(6), 1470-1476.
130. Gerweck, L.E. Tumor pH: implications for treatment and novel drug design. Semin. Rad. Oncol., 1998, 8(3), 176-182.
131. Stillebroer, A.B.; Mulders, P.F.; Boerman, O.C.; Oyen, W.J.; Oosterwijk, E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur. Urol., 2010, 58(1), 75-83.
132. Wykoff, C.C.; Beasley, N.J.; Watson, P.H.; Turner, K.J.; Pastorek, J.; Sibtain, A.; Wilson, G.D.; Turley, H.; Talks, K.L.; Maxwell, P.H.; Pugh, C.W.; Ratcliffe, P.J.; Harris, A.L. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res., 2000, 60(24), 7075-7083.
133. Tostain, J.; Li, G.; Gentil-Perret, A.; Gigante, M. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur. J. Cancer, 2010, 46(18), 3141-3148.
134. Wang, Y.; Wang, X.Y.; Subjeck, J.R.; Kim, H.L. Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant. Mol. Cancer Ther., 2008, 7(12), 3867-3877.
135. Dorai, T.; Sawczuk, I.S.; Pastorek, J.; Wiernik, P.H.; Dutcher, J.P. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur. J. Cancer, 2005, 41(18), 2935-2947.
136. Turner, K.J.; Crew, J.P.; Wykoff, C.C.; Watson, P.H.; Poulsom, R.; Pastorek, J.; Ratcliffe, P.J.; Cranston, D.; Harris, A.L. The hypoxiainducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Brit. J. Cancer, 2002, 86(8), 1276-1282.
137. Chen, J.; Rocken, C.; Hoffmann, J.; Kruger, S.; Lendeckel, U.; Rocco, A.; Pastorekova, S.; Malfertheiner, P.; Ebert, M.P. Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut, 2005, 54(7), 920-927.
138. Cho, M.; Uemura, H.; Kim, S.C.; Kawada, Y.; Yoshida, K.; Hirao, Y.; Konishi, N.; Saga, S.; Yoshikawa, K. Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. Brit. J. Cancer, 2001, 85(4), 563-567.
139. Nakamura, J.; Kitajima, Y.; Kai, K.; Hashiguchi, K.; Hiraki, M.; Noshiro, H.; Miyazaki, K. Expression of hypoxic marker CA IX is regulated by site-specific DNA methylation and is associated with the histology of gastric cancer. Am. J. Pathol., 2011, 178(2), 515-524.
140. Buanne, P.; Renzone, G.; Monteleone, F.; Vitale, M.; Monti, S.M.; Sandomenico, A.; Garbi, C.; Montanaro, D.; Accardo, M.; Troncone, G.; Zatovicova, M.; Csaderova, L.; Supuran, C.T.; Pastorekova, S.; Scaloni, A.; De Simone, G.; Zambrano, N. Characterization of carbonic anhydrase IX interactome
141. Dungwa, J.V.; Hunt, L.P.; Ramani, P. Carbonic anhydrase IX upregulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas. Human Pathol., 2012, 43(10), 1651-1660.
142. Horswell, S.; Matthews, N.; Swanton, C. Cancer heterogeneity and The Struggle for Existence: Diagnostic and analytical challenges. Cancer Lett., 2013, 340(2), 220-226.
143. Kwak, E.L.; Bang, Y.J.; Camidge, D.R.; Shaw, A.T.; Solomon, B.; Maki, R.G.; Ou, S.H.; Dezube, B.J.; Janne, P.A.; Costa, D.B.; Varella-Garcia, M.; Kim, W.H.; Lynch, T.J.; Fidias, P.; Stubbs, H.; Engelman, J.A.; Sequist, L.V.; Tan, W.; Gandhi, L.; Mino-Kenudson, M.; Wei, G.C.; Shreeve, S.M.; Ratain, M.J.; Settleman, J.; Christensen, J.G.; Haber, D.A.; Wilner, K.; Salgia, R.; Shapiro, G.I.; Clark, J.W.; Iafrate, A.J. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New Engl. J. Med., 2010, 363(18), 1693-1703.
144. Rosti, G.; Castagnetti, F.; Gugliotta, G.; Palandri, F.; Baccarani, M. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. Crit. Rev. Oncol. Hematol., 2012, 82(2), 159-170.
145. Flaherty, K.T.; Puzanov, I.; Kim, K.B.; Ribas, A.; McArthur, G.A.; Sosman, J.A.; O'Dwyer, P.J.; Lee, R.J.; Grippo, J.F.; Nolop, K.; Chapman, P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl. J. Med., 2010, 363(9), 809-819.
146. Sampson, J.H.; Heimberger, A.B.; Archer, G.E.; Aldape, K.D.; Friedman, A.H.; Friedman, H.S.; Gilbert, M.R.; Herndon, J.E., 2nd; McLendon, R.E.; Mitchell, D.A.; Reardon, D.A.; Sawaya, R.; Schmittling, R.J.; Shi, W.; Vredenburgh, J.J.; Bigner, D.D. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol., 2010, 28(31), 4722-4729.
147. Garraway, L.A.; Janne, P.A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov., 2012, 2(3), 214-226.
148. Nowell, P.C. The clonal evolution of tumor cell populations. Science, 1976, 194(4260), 23-28.
149. Monti, S.M.; Supuran, C.T.; De Simone, G. Carbonic anhydrase IX as a target for designing novel anticancer drugs. Curr. Med. Chem., 2012, 19(6), 821-830.
150. De Simone, G. Zinc metallo-enzymes as target for drug design. Curr. Med. Chem., 2012, 19(6), 820.
151. Guler, O.O.; De Simone, G.; Supuran, C.T. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII. Curr. Med. Chem., 2010, 17(15), 1516-1526.
152. Bleumer, I.; Knuth, A.; Oosterwijk, E.; Hofmann, R.; Varga, Z.; Lamers, C.; Kruit, W.; Melchior, S.; Mala, C.; Ullrich, S.; De Mulder, P.; Mulders, P.F.; Beck, J. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Brit. J. Cancer, 2004, 90(5), 985-990.
153. Zatovicova, M.; Jelenska, L.; Hulikova, A.; Csaderova, L.; Ditte, Z.; Ditte, P.; Goliasova, T.; Pastorek, J.; Pastorekova, S. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr. Pharm. Des., 2010, 16(29), 3255-3263.
154. Murri-Plesko, M.T.; Hulikova, A.; Oosterwijk, E.; Scott, A.M.; Zortea, A.; Harris, A.L.; Ritter, G.; Old, L.; Bauer, S.; Swietach, P.; Renner, C. Antibody inhibiting enzymatic activity of tumourassociated carbonic anhydrase isoform IX. Eur. J. Pharmacol., 2011, 657(1-3), 173-183.
155. Xu, C.; Lo, A.; Yammanuru, A.; Tallarico, A.S.; Brady, K.; Murakami, A.; Barteneva, N.; Zhu, Q.; Marasco, W.A. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PloS One, 2010, 5(3), e9625.
156. Maresca, A.; Supuran, C.T. Coumarins incorporating hydroxy-and chloro-moieties selectively inhibit the transmembrane, tumorassociated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II. Bioorg. Med. Chem. Lett., 2010, 20(15), 4511-4514.
157. Maresca, A.; Scozzafava, A.; Supuran, C.T. 7,8-disubstituted-but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. Bioorg. Med. Chem. Lett., 2010, 20(24), 7255-7258.
158. Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran, C.T. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem., 2004, 19(3), 199-229.
159. Al-Lazikani, B.; Banerji, U.; Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol., 2012, 30(7), 679-692.
160. Zavada, J.; Zavadova, Z.; Zat'ovicova, M.; Hyrsl, L.; Kawaciuk, I. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Brit. J. Cancer, 2003, 89(6), 1067-1071.
161. Hyrsl, L.; Zavada, J.; Zavadova, Z.; Kawaciuk, I.; Vesely, S.; Skapa, P. Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract. Neoplasma, 2009, 56(4), 298-302.
162. Zhou, G.X.; Ireland, J.; Rayman, P.; Finke, J.; Zhou, M. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. Urology, 2010, 75(2), 257-261.
163. Zatovicova, M.; Sedlakova, O.; Svastova, E.; Ohradanova, A.; Ciampor, F.; Arribas, J.; Pastorek, J.; Pastorekova, S. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Brit. J. Cancer, 2005, 93(11), 1267-1276.
164. Kock, L.; Mahner, S.; Choschzick, M.; Eulenburg, C.; Milde-Langosch, K.; Schwarz, J.; Jaenicke, F.; Muller, V.; Woelber, L. Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer. Int. J. Gynecol. Cancer, 2011, 21(1), 141-148.
165. Muller, V.; Riethdorf, S.; Rack, B.; Janni, W.; Fasching, P.A.; Solomayer, E.; Aktas, B.; Kasimir-Bauer, S.; Zeitz, J.; Pantel, K.; Fehm, T. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. Breast Cancer Res., 2011, 13(4), R71.
166. Li, G.; Feng, G.; Gentil-Perret, A.; Genin, C.; Tostain, J. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J. Urol., 2008, 180(2), 510-513; discussion 513-514.
167. Woelber, L.; Mueller, V.; Eulenburg, C.; Schwarz, J.; Carney, W.; Jaenicke, F.; Milde-Langosch, K.; Mahner, S. Serum carbonic anhydrase IX during first-line therapy of ovarian cancer. Gynecol. Oncol., 2010, 117(2), 183-188.
168. Woodcock, J. Assessing the clinical utility of diagnostics used in drug therapy. Clin. Pharmacol. Ther., 2010, 88(6), 765-773.